News articles about Veracyte (NASDAQ:VCYT) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Veracyte earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.2878149665868 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s analysis:
Several brokerages recently weighed in on VCYT. Piper Jaffray Companies reiterated a “buy” rating on shares of Veracyte in a research report on Tuesday, September 12th. BTIG Research reiterated a “buy” rating and set a $13.00 price target on shares of Veracyte in a research report on Thursday, August 31st. Zacks Investment Research cut Veracyte from a “hold” rating to a “sell” rating in a research report on Thursday, October 12th. Janney Montgomery Scott cut Veracyte from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 7th. Finally, ValuEngine cut Veracyte from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. Veracyte currently has an average rating of “Hold” and an average price target of $11.85.
Shares of Veracyte (NASDAQ:VCYT) opened at $6.63 on Tuesday. The company has a current ratio of 5.19, a quick ratio of 4.86 and a debt-to-equity ratio of 0.59. Veracyte has a 12-month low of $5.75 and a 12-month high of $9.80.
Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.21) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.21). The firm had revenue of $17.50 million during the quarter, compared to analysts’ expectations of $19.54 million. Veracyte had a negative return on equity of 52.99% and a negative net margin of 38.19%. The firm’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.20) earnings per share. sell-side analysts anticipate that Veracyte will post -0.87 EPS for the current fiscal year.
In other news, insider Christopher M. Hall sold 20,000 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $9.00, for a total value of $180,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Bonnie H. Anderson sold 16,000 shares of the company’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $9.41, for a total value of $150,560.00. Following the completion of the transaction, the chairman now directly owns 16,000 shares in the company, valued at approximately $150,560. The disclosure for this sale can be found here. Insiders have sold 48,000 shares of company stock worth $435,740 in the last three months. 13.40% of the stock is currently owned by corporate insiders.
WARNING: “Veracyte (VCYT) Receiving Somewhat Positive Press Coverage, Study Shows” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-veracyte-vcyt-stock-price.html.
Veracyte Company Profile
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.